The dispute between the U.S. and China is more than a question of tariffs, says René Buck, CEO of BCI Global. It involves complex matters of intellectual property and re-sourcing.

The trade standoff between the U.S. and China has yet to seriously impact the pharmaceutical and life sciences industries. But as neither side shows signs of backing down, and tariffs continue to be levied on virtually every segment, those sectors are preparing for a major supply-chain disruption.

Yet another chapter in the chaotic Brexit story has been written, with the scheduling of a general election in Britain on December 12, to determine the fate of Prime Minister Boris Johnson and his embattled government. 

The decision about whether to keep manufacturing in China or seek other sources must take into account multiple factors, some of them less obvious than others, says Mark Baxa, president and CEO of FerniaCreek LLC.

Tech manufacturers have led a shift in the relationship between business and society. It has been a driver of progress while raising questions about some outcomes. High tech businesses can plan for the future by deploying intelligent ERP that builds trust and accelerates business and societal growth.